New GLP-1 RA ‘better than semaglutide’ for weight loss in Lancet study
A high dose of a new once-weekly injected GLP-1 receptor agonist has outdone semaglutide for weight loss in a phase III trial. Ecnoglutide, developed in…
A high dose of a new once-weekly injected GLP-1 receptor agonist has outdone semaglutide for weight loss in a phase III trial. Ecnoglutide, developed in…
Telehealth corporate Eucalyptus is embroiled in a legal battle with the Uniting Church over its online weight loss program Juniper with the church alleging it…
Something I’ve struggled with my whole life is my weight. Not because I’m unhappy with my body, but because others seem to be. Let me…
Are bariatric surgeons in trouble? Many are facing sky-high premiums fuelled by an apparent rise in patient complaints. And what about the GLP-1s? Will they…
UK Secretary of State for Health and Social Care Wes Streeting. AAP.There are many wondrous things about GLP-1 receptor agonists, not least their capacity to…
Tirzepatide leads to greater weight loss than semaglutide in adults with obesity but without type 2 diabetes, a head-to-head trial suggests. Published in the New…
GPs who prescribe semaglutide should be obliged to also refer those patients on to a dietitian for appropriate counselling, Dietitians Australia says. The organisation’s president…
Semaglutide is a game changer for patients right up until they stop the treatment, when many face the heartbreak of watching the kilos return. That…
BMI can be used to diagnose obesity but only in conjunction with other measures of body fat, according to a landmark international statement. A Lancet…
Pharmaceutical giant Eli Lilly is readying a PBAC application for tirzepatide, which if successful, would become the first GLP-1 receptor agonist publicly funded for obesity…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.